UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

Under the Securities Exchange Act of 1934 (Amendment No. _)*

LEXICON PHARMACEUTICALS, INC. (Name of Issuer)

COMMON STOCK, PAR VALUE \$0.001 PER SHARE (Title of Class of Securities)

> 528872104 (CUSIP Number)

JUNE 15, 2007

(Date of Event Which Requires Filing of this Statement)						
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:						
☐ Rule 13d-1(b)[X] Rule 13d-1(c)☐ Rule 13d-1(d)						
The remainder of this cover page shall be filled out for a reporting person's nitial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.						
The information required on the reminder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).						
CUSIP No. 528872104 Page 2 of 20 Schedule 13G						
NAMES OF REPORTING PERSON S.S OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
Symphony Capital Partners, L.P.						
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (b) [X]						
3 SEC USE ONLY						
CITIZENSHIP OR PLACE OF ORGANIZATION						
Delaware						
5 SOLE VOTING POWER						
NUMBER OF 4,954,745						
SHARES BENEFICIALLY 6 SHARED VOTING POWER						

4,954,745

7 SOLE DISPOSITIVE POWER

8 SHARED DISPOSITIVE POWER

OWNED BY EACH

REPORTING PERSON

-0-

	4,954,745
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	5.8%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	PN

4,954,745

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.8%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

-0-

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,954,745

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.8%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

00

.....

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CERTAIN SHARES (SEE INSTRUCTIONS)

374,869

00

5,329,614

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.2%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

,

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CERTAIN SHARES (SEE INSTRUCTIONS)

5,329,614

5,329,614

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.2%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IN

Item 1. (a) NAME OF ISSUER

Lexicon Pharmaceuticals, Inc. (the "Company").

(b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES

8800 Technology Forest Place, The Woodlands, Texas 77381

Item 2. (a) NAMES OF PERSONS FILING

This Statement is being filed on behalf of each of the following persons (collectively, the "Reporting Persons")

- Symphony Capital Partners, L.P. ("SCP")
- (ii) Symphony Capital GP, L.P. ("Symphony Capital GP")
 (iii) Symphony GP, LLC ("Symphony GP")
 (iv) Symphony Strategic Partners, LLC ("SSP")

- (v) Mark Kessel
- (vi) Neil J. Sandler
- (vii) Harri V. Taranto

(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE

The address of the principal business offices of the Reporting Persons is 875 Third Avenue, 18th Floor, New York, NY 10022

(c) CITIZENSHIP

- (i) SCP a Delaware limited partnership(ii) Symphony Capital GP a Delaware limited partnership
- (iii) Symphony GP a Delaware limited liability company
- (iv) SSP a Delaware limited liability company
- Mark Kessel a citizen of the United States (v)
- (vi) Neil J. Sandler a citizen of the United States
- (vii) Harri V. Taranto a citizen of the United States

(d) TITLE OF CLASS OF SECURITIES

Common Stock, par value \$0.001 per share (the "Common Stock" or "Shares")

(e) CUSIP NUMBER

528872104

Item 3. This statement is not being filed pursuant to either Rule 13d-1(b) or 13d-2(b) or (c).

Item 4. OWNERSHIP.

(a) AMOUNT BENEFICIALLY OWNED:

- (i) Each of SCP, Symphony Capital GP and Symphony GP may be deemed to beneficially own an aggregate of 4,954,745 Shares.
- (ii) SSP may be deemed to beneficially own an aggregate of $374,869\ \text{Shares}$.
- (iii) Each of Mark Kessel, Neil J. Sandler and Harri V. Taranto may be deemed to beneficially own an aggregate of 5.329.614 Shares.

(b) PERCENTAGE OWNED:

Based on calculations made in accordance with Rule 13d-3(d), and there being 85,961,249 Shares outstanding as of June 15, 2007, (i) each of SCP, Symphony Capital GP and Symphony GP may be deemed to own approximately 5.8% of the outstanding Common Stock, (ii) SSP may be deemed to own approximately 0.4% of the outstanding Common Stock, and (iii) each of Mark Kessel, Neil J. Sandler and Harri V. Taranto may be deemed to beneficially own approximately 6.2% of the outstanding Common Stock.

(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

- (i) Each of SCP, Symphony Capital GP, Symphony GP may be deemed to have sole power to direct the voting and disposition of 4,954,745 Shares.
- (ii) SSP may be deemed to have sole power to direct the voting and disposition of 374,869 Shares.
- (iii) Each of Mark Kessel, Neil J. Sandler and Harri V. Taranto may be deemed to have shared power to direct the voting and disposition of 5,329,614 Shares.

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

Not applicable.

Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Not applicable.

Item 7. IDENTIFICATION AND CLASSIFICATION OF SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not applicable.

Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

See Item 2.

Item 9. NOTICE OF DISSOLUTION OF GROUP

Not applicable.

Item 10. CERTIFICATION

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated as of June 25, 2007

SYMPHONY CAPITAL PARTNERS, L.P.

By: Symphony Capital GP, L.P. its general partner

By: Symphony GP, LLC its general partner

By: /s/ Mark Kessel

Name: Mark Kessel
Title: Managing Member

SYMPHONY STRATEGIC PARTNERS, LLC

By: /s/ Mark Kessel

- ------

SYMPHONY CAPITAL GP, L.P.

By: Symphony GP, LLC its general partner

By: /s/ Mark Kessel

Name: Mark Kessel Title: Managing Member

SYMPHONY GP, LLC

By: /s/ Mark Kessel

MARK KESSEL

By: /s/ Mark Kessel

Name: Mark Kessel Title: Managing Member

NEIL J. SANDLER

By: /s/ Neil J. Sandler

Name: Neil J. Sandler Title: Managing Member

HARRI V. TARANTO

By: /s/ Harri V. Tarranto

Name: Harri V. Taranto Title: Managing Member CUSIP No. 528872104 Page 16 of 20 Schedule 13G

EXHIBIT INDEX

Exhibit 1. Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

EXHIBIT 1

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1)

Dated as of June 25, 2007

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized, as of the date first above written.

SYMPHONY CAPITAL PARTNERS, L.P.

By: Symphony Capital GP, L.P. its general partner

By: Symphony GP, LLC its general partner

By: /s/ Mark Kessel

Name: Mark Kessel Title: Managing Member

SYMPHONY STRATEGIC PARTNERS, LLC

By: /s/ Mark Kessel

SYMPHONY CAPITAL GP, L.P.

By: Symphony GP, LLC its general partner

By: /s/ Mark Kessel

Name: Mark Kessel Title: Managing Member

SYMPHONY GP, LLC

By: /s/ Mark Kessel

MARK KESSEL

By: /s/ Mark Kessel

Name: Mark Kessel Title: Managing Member

NEIL J. SANDLER

By: /s/ Neil J. Sandler

Name: Neil J. Sandler Title: Managing Member

HARRI V. TARANTO

By: /s/ Harri V. Tarranto

Name: Harri V. Taranto Title: Managing Member